Literature DB >> 36033974

Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

Deyu Li1, Na Li2, Ying Ding3.   

Abstract

The present study aimed to explore the epithelial-to-mesenchymal transition of circulating tumor cells (CTCs) and CD133 expression in determining the prognosis of patients with thyroid cancer. It enumerated different CTC subtypes and analyzed CD133 gene expression in patients with thyroid cancer to evaluate the relationship between CTC number and thyroid cancer prognosis. In total 394 patients with thyroid cancer were enrolled. Among these, 270 cases had papillary thyroid cancer (PTC), 60 had follicular thyroid cancer (FTC), 30 had medullary thyroid cancer (MTC), 15 had poorly differentiated thyroid cancer, 19 had anaplastic thyroid cancer and 10 had non-malignant thyroid nodules based on their histopathological characteristics. CTC cell counts were determined by CanPatrol CTC capture technique before treatment. The present study also performed reverse transcription-quantitative PCR for CD133 gene expression and evaluated the relationship between CD133 expression and clinical pathology. A total of 330 cases of enrolled patients were classified as differentiated thyroid cancer, which included PTC and FTC. Their prognosis was excellent. The positivity rate of CTCs at diagnosis was 95.5%. The data of the present study showed that early recurrence and metastasis rates in PTC and FTC patients with >6 CTCs and positive mesenchymal circulating tumor cells (MCTCs) were significantly higher than those in patients with <6 CTCs and MCTCs. It was also found that those patients with >6 CTCs and MCTCs had shorter overall survival. In addition, CD133 levels in patients with thyroid cancer were strongly associated with the differentiation grades of thyroid cancers. The detection of >6 CTCs and positive MCTCs in patients with differentiated thyroid cancer was an excellent biomarker for predicting the prognosis of patients. CD133 expression was also identified as a good biomarker for thyroid cancer differentiation.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  CD133; circulating tumor cells; prognosis; progression free survival; thyroid cancer

Year:  2022        PMID: 36033974      PMCID: PMC9403616          DOI: 10.3892/mco.2022.2574

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  54 in total

1.  Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

Review 2.  Clinical indications for, and the future of, circulating tumor cells.

Authors:  Dominic H Moon; Daniel P Lindsay; Seungpyo Hong; Andrew Z Wang
Journal:  Adv Drug Deliv Rev       Date:  2018-04-05       Impact factor: 15.470

3.  Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein.

Authors:  D Corbeil; C A Fargeas; W B Huttner
Journal:  Biochem Biophys Res Commun       Date:  2001-07-27       Impact factor: 3.575

4.  Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer.

Authors:  Zhong-Ling Qiu; Wei-Jun Wei; Zhen-Kui Sun; Chen-Tian Shen; Hong-Jun Song; Xin-Yun Zhang; Guo-Qiang Zhang; Xiao-Yue Chen; Quan-Yong Luo
Journal:  Cell Physiol Biochem       Date:  2018-07-19

5.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Authors:  Jian-Mei Hou; Matthew G Krebs; Lee Lancashire; Robert Sloane; Alison Backen; Rajeeb K Swain; Lynsey J C Priest; Alastair Greystoke; Cong Zhou; Karen Morris; Tim Ward; Fiona H Blackhall; Caroline Dive
Journal:  J Clin Oncol       Date:  2012-01-17       Impact factor: 44.544

6.  Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence?

Authors:  Noriyoshi Sawabata; Toshitaka Nakamura; Takeshi Kawaguchi; Takashi Watanabe; Noriko Sageshima Ouji; Toshihiro Ito; Shigeki Taniguchi
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

7.  Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation.

Authors:  Peng-Xiang Wang; Yang Xu; Yun-Fan Sun; Jian-Wen Cheng; Kai-Qian Zhou; Sui-Yi Wu; Bo Hu; Ze-Fan Zhang; Wei Guo; Ya Cao; Xiao-Wu Huang; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Liver Int       Date:  2020-11-29       Impact factor: 5.828

8.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

Review 9.  Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells.

Authors:  Douglas S Micalizzi; Daniel A Haber; Shyamala Maheswaran
Journal:  Mol Oncol       Date:  2017-06-09       Impact factor: 6.603

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.